Identification
- Summary
Sulfanilamide is a sulfonamide anti-infective used to treat vulvovaginal candidiasis caused by Candida albicans.
- Generic Name
- Sulfanilamide
- DrugBank Accession Number
- DB00259
- Background
Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sulfanilamide (DB00259)
- Weight
- Average: 172.205
Monoisotopic: 172.0306482 - Chemical Formula
- C6H8N2O2S
- Synonyms
- 4-aminobenzene sulfonic acid amide
- 4-azanylbenzenesulfonamide
- p-aminobenzenesulfamide
- p-aminobenzenesulfonamide
- para-aminobenzenesulfonamide
- Prontosil album
- SA
- Streptocide
- Sulfamine
- Sulfanilamida
- Sulfanilamide
- Sulfanilamidum
- Sulphanilamide
- External IDs
- 1162 F
- F 1162
- F-1162
- NSC-7618
Pharmacology
- Indication
For the treatment of vulvovaginitis caused by Candida albicans.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Sulfanilamide is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
- Mechanism of action
Sulfanilamide is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. This enzyme normally uses para-aminobenzoic acid (PABA) for synthesizing the necessary folic acid. The inhibited reaction is normally necessary in these organisms for the synthesis of folic acid. Without it, bacteria cannot replicate.
Target Actions Organism ADihydropteroate synthase inhibitorEscherichia coli (strain K12) - Absorption
Sulfonamides are absorbed through the vaginal mucosa. There are no pharmacokinetic data available describing how much of an intravaginal dose reaches the systemic circulation.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Oral, mouse LD50 = 3700 mg/kg; Intravenous, mouse LD50 = 621 mg/kg; Oral, rabbit LD50 = 1300 mg/kg. Side effects include itching, burning, skin rash, redness, swelling, or other sign of irritation not present before use of this medicine and long-term use of sulfonamides may cause cancer of the thyroid gland.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareArticaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Articaine. Belzutifan The serum concentration of Belzutifan can be increased when it is combined with Sulfanilamide. Benzocaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Benzyl alcohol. Benzylpenicillin Sulfanilamide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. Bupivacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Capsaicin. Chloroprocaine The therapeutic efficacy of Sulfanilamide can be decreased when used in combination with Chloroprocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Streptocid
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Avc Cream 15 g/100g Vaginal MEDA Pharmaceuticals 2014-12-01 2019-09-30 US 
Avc Cream - 15% Cream 15 % Vaginal Hoechst Marion Roussel 1995-12-31 2000-07-28 Canada 
AVC Vaginal Cream 15 g/100g Vaginal Jazz Pharmaceuticals Commercial Corp. 1965-06-05 2016-12-31 US AVC Vaginal Cream 15 g/100g Vaginal Physicians Total Care, Inc. 1965-06-05 2012-06-30 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image บุษบา Sulfanilamide (99.3 G/100G) + Tannic acid (0.41 G/100G) Powder Topical บริษัท ไบร์วู๊ดฟาร์มาซูติคอล จำกัด 1986-12-29 2019-10-21 Thailand 
บุษบา ไบร์วู๊ด Sulfanilamide (99.3 G/100G) + Tannic acid (0.41 G/100G) Powder Topical บริษัท ไบร์วู๊ดฟาร์มาซูติคอล จำกัด 1997-08-26 2019-10-21 Thailand ยาผง เอ็มบีซี Sulfanilamide (25 G/100G) + Octasulfur (16.5 G/100G) + Zinc oxide (25 G/100G) Powder Topical ห้างหุ้นส่วนจำกัด ห้างขายยา กรุงเทพฯฟามาซี 1984-08-15 Not applicable Thailand ยาผงพิเศษ ตราร่มชูชีพ Sulfanilamide (99.3 G/100G) + Tannic acid (0.41 G/100G) Powder Topical บริษัท สมจิตต์โอสถ จำกัด 1986-04-24 Not applicable Thailand ยาผงอารายา Sulfanilamide (99.3 G/100G) + Tannic acid (0.41 G/100G) Powder Topical บริษัท ฮีโร่มัยซิน ฟาร์ม่า จำกัด จำกัด 2004-02-11 2020-08-23 Thailand
Categories
- ATC Codes
- G01AE10 — Combinations of sulfonamides
- G01AE — Sulfonamides
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- J01EB — Short-acting sulfonamides
- J01E — SULFONAMIDES AND TRIMETHOPRIM
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Amides
- Amines
- Aniline Compounds
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologicals
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Methemoglobinemia Associated Agents
- Short-Acting Antibacterial Sulfonamides
- Sulfanilamides
- Sulfonamide Antibacterial
- Sulfonamides
- Sulfonamides and trimethoprim
- Sulfones
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Aminobenzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Aniline and substituted anilines / Organosulfonamides / Aminosulfonyl compounds / Primary amines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Amine / Aminobenzenesulfonamide / Aminosulfonyl compound / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzenesulfonyl group / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- substituted aniline, sulfonamide, sulfonamide antibiotic (CHEBI:45373)
- Affected organisms
- Candida albicans and other yeasts
Chemical Identifiers
- UNII
- 21240MF57M
- CAS number
- 63-74-1
- InChI Key
- FDDDEECHVMSUSB-UHFFFAOYSA-N
- InChI
- InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
- IUPAC Name
- 4-aminobenzene-1-sulfonamide
- SMILES
- NC1=CC=C(C=C1)S(N)(=O)=O
References
- Synthesis Reference
Donald R. Randell, Emyr Phillips, "Anthraquinone sulphonamide compounds and preparation." U.S. Patent US4276224, issued May, 1937.
US4276224- General References
- Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7. [Article]
- External Links
- Human Metabolome Database
- HMDB0014404
- KEGG Drug
- D08543
- KEGG Compound
- C07458
- PubChem Compound
- 5333
- PubChem Substance
- 46508306
- ChemSpider
- 5142
- BindingDB
- 10857
- 10184
- ChEBI
- 45373
- ChEMBL
- CHEMBL21
- ZINC
- ZINC000000002101
- Therapeutic Targets Database
- DNC001391
- PharmGKB
- PA451545
- PDBe Ligand
- SAN
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Sulfanilamide
- PDB Entries
- 1aj0 / 4coq / 4f92 / 4f93 / 6rl9
- MSDS
- Download (74.9 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Azur pharma international ltd
- Teva pharmaceuticals usa inc
- Packagers
- Mallinckrodt Inc.
- Pharmedix
- Pharmelle LLC
- Physicians Total Care Inc.
- Sanofi-Aventis Inc.
- Dosage Forms
Form Route Strength Cream Vaginal 15 % Cream Vaginal 15 g/100g Powder Topical - Prices
Unit description Cost Unit AVC Vaginal 15% Cream 120 gm Tube 110.97USD tube Avc 15% cream 0.33USD g Sodium sulfanilamide powder 0.22USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 165.5 °C PhysProp water solubility 7500 mg/L (at 25 °C) MERCK INDEX (1976) logP -0.62 HANSCH,C ET AL. (1995) logS -1.36 ADME Research, USCD pKa 10.6 (at 20 °C) SERJEANT,EP & DEMPSEY,B (1979) - Predicted Properties
Property Value Source Water Solubility 10.4 mg/mL ALOGPS logP -0.16 ALOGPS logP -0.25 Chemaxon logS -1.2 ALOGPS pKa (Strongest Acidic) 10.99 Chemaxon pKa (Strongest Basic) 2.27 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 86.18 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 42.92 m3·mol-1 Chemaxon Polarizability 16.25 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9893 Blood Brain Barrier + 0.9795 Caco-2 permeable + 0.5881 P-glycoprotein substrate Non-substrate 0.9243 P-glycoprotein inhibitor I Non-inhibitor 0.969 P-glycoprotein inhibitor II Non-inhibitor 0.9313 Renal organic cation transporter Non-inhibitor 0.9254 CYP450 2C9 substrate Non-substrate 0.8093 CYP450 2D6 substrate Non-substrate 0.9117 CYP450 3A4 substrate Non-substrate 0.7625 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9418 CYP450 2D6 inhibitor Non-inhibitor 0.9478 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8891 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8059 Ames test Non AMES toxic 0.9253 Carcinogenicity Non-carcinogens 0.8711 Biodegradation Not ready biodegradable 0.9867 Rat acute toxicity 1.6762 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9432 hERG inhibition (predictor II) Non-inhibitor 0.9451
Spectra
- Mass Spec (NIST)
- Download (9 KB)
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
- Gene Name
- folP
- Uniprot ID
- P0AC13
- Uniprot Name
- Dihydropteroate synthase
- Molecular Weight
- 30614.855 Da
References
- Djapa LY, Zelikson R, Delahodde A, Bolotin-Fukuhara M, Mazabraud A: Plasmodium vivax dihydrofolate reductase as a target of sulpha drugs. FEMS Microbiol Lett. 2006 Mar;256(1):105-11. [Article]
- Nzila A: Inhibitors of de novo folate enzymes in Plasmodium falciparum. Drug Discov Today. 2006 Oct;11(19-20):939-44. Epub 2006 Sep 7. [Article]
- Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 03, 2022 21:06